|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
1/2016
vol. 118 abstract:
Review paper
Use of nonsteroidal anti-inflammatory drugs in diabetic retinopathy
Grażyna Malukiewicz
1
,
Joanna Stafiej
1
,
Hanna Lesiewska
1
,
Bartosz Sikorski
1
Online publish date: 2017/11/29
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Introduction
Diabetic macular edema, a manifestation of diabetic retinopathy, occurs more frequently in type 2 diabetes mellitus. There is evidence that inflammation plays a prominent role in the pathogenesis. A number of pro-inflammatory cytokines are consistently elevated in the vitreous of patients with advanced stages of diabetic retinopathy. Nonsteroidal anti-inflammatory drugs inhibit the catalytic activity of the cyclooxygenase isoenzymes COX-1 and COX-2, the key enzymes in inflammatory processes. Purpose To present current knowledge of benefits and limitations of using nonsteroidal anti-inflammatory drugs in diabetic retinopathy. Conclusions Nonsteroidal anti-inflammatory drugs may be considered as an adjuvant treatment in diabetic retinopathy especially in patients with diabetic macular edema. keywords:
diabetic retinopathy, diabetic macular edema, nonsteroidal anti-inflammatory drugs |
|
POLSKI
